On July 16th, 2012, the US Food and Drug Administration approved the first drug for reducing the risk of HIV infection. Gilead Science’s Truvada is actually based in part on technology developed at Emory (Emtriva). In Truvada, a fixed dose of Emtriva (Emtricitabine) is combined with Tenofovir. This exciting news for HIV prophylaxis comes shortly after recent FDA approval of the OraQuick test earlier this month for the detection of HIV using an oral saliva swab.
Visit this link to read more about Truvada and HIV prevention: http://www.huffingtonpost.com/2012/07/16/truvada-fda-hiv-prevent_n_1677020.html